These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 29526541

  • 1. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
    Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.
    Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI, Bunz TJ, Turpie AGG.
    Thromb Haemost; 2017 Oct 05; 117(10):1841-1847. PubMed ID: 28640322
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J.
    Thromb Res; 2018 Mar 05; 163():132-137. PubMed ID: 29407625
    [Abstract] [Full Text] [Related]

  • 4. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI.
    Eur J Haematol; 2019 Feb 05; 102(2):143-149. PubMed ID: 30328143
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.
    J Thromb Thrombolysis; 2018 Oct 05; 46(3):339-345. PubMed ID: 29881958
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK, Seago SE, Garza JE, Hashimie YF, Baty KA, Evans MF, Shaver C, Herrington JD.
    J Oncol Pharm Pract; 2018 Oct 05; 24(7):494-500. PubMed ID: 28714376
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR, Gandhi AS.
    J Oncol Pharm Pract; 2019 Mar 05; 25(2):362-368. PubMed ID: 29157146
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
    Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Sood N.
    Cardiovasc Diabetol; 2021 Feb 26; 20(1):52. PubMed ID: 33637082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.